

ESTTA Tracking number: **ESTTA355123**

Filing date: **06/28/2010**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

## Notice of Opposition

Notice is hereby given that the following party opposes registration of the indicated application.

### Opposer Information

Name	Roche Therapeutics Inc.
Granted to Date of previous extension	06/30/2010
Address	340 Kingsland Street Nutley, NJ 07110 UNITED STATES
Attorney information	Elizabeth Atkins Lathrop & Gage LLP 230 Park Avenue Suite 1847 New York, NY 10169 UNITED STATES eatkins@lathropgage.com, tfitzgerald@lathropgage.com

### Applicant Information

Application No	77744250	Publication date	03/02/2010
Opposition Filing Date	06/28/2010	Opposition Period Ends	06/30/2010
Applicant	DAIICHI SANKYO COMPANY, LIMITED 3-5-1, Nihonbashi Honcho, Chuo-ku Tokyo, 103-8426 JAPAN		

### Goods/Services Affected by Opposition

Class 005. All goods and services in the class are opposed, namely: Pharmaceutical preparations for the treatment and prevention of cardiovascular disease, atherosclerosis, diabetic nephropathy, stroke, heart attack, hypercholesterolemia, dyslipidemia, anemia, blood disorders, diabetes, thyroid function disease, metabolic disorders, cancer, oncological disease, metastasis, autoimmune disease, allergy, bacterial infection, viral infection, fungal infection, inflammation and inflammatory disease, musculoskeletal disorders, pain, osteoporosis, Alzheimer's disease, obesity, anorexia, urinary and kidney disease, respiratory disease; Diagnostic reagents and contrast media for medical use
---


### Grounds for Opposition


Priority and likelihood of confusion	Trademark Act section 2(d)
Dilution	Trademark Act section 43(c)


### Marks Cited by Opposer as Basis for Opposition

U.S. Registration No.	2931724	Application Date	01/31/2003
-----------------------	---------	------------------	------------

Registration Date	03/08/2005	Foreign Priority Date	NONE
Word Mark	BONIVA		
Design Mark			
Description of Mark	NONE		
Goods/Services	Class 005. First use: First Use: 2004/08/24 First Use In Commerce: 2004/08/24 pharmaceutical preparation for the prevention and treatment of bone diseases		

U.S. Registration No.	3165165	Application Date	12/01/2005
Registration Date	10/31/2006	Foreign Priority Date	NONE
Word Mark	BONIVA IBANDRONATE SODIUM TABLETS ONCE-MONTHLY		
Design Mark			
Description of Mark	NONE		
Goods/Services	Class 044. First use: First Use: 2005/07/26 First Use In Commerce: 2005/07/26 providing health information via an internet web site, namely providing educational information directed to patients and physicians regarding osteoporosis and treatment options		

U.S. Registration No.	3213515	Application Date	06/08/2006
Registration Date	02/27/2007	Foreign Priority Date	NONE
Word Mark	ONCE-MONTHLY BONIVA IBANDRONATE SODIUM TABLETS		
Design Mark			
Description of Mark	The mark consists of stylized figure of a woman.		
Goods/Services	Class 016. First use: First Use: 2005/10/12 First Use In Commerce: 2005/10/12		

	printed brochures in the field of the prevention and treatment of bone diseases		
U.S. Registration No.	3234766	Application Date	04/13/2005
Registration Date	04/24/2007	Foreign Priority Date	NONE
Word Mark	MYBONIVA		
Design Mark			
Description of Mark	NONE		
Goods/Services	Class 044. First use: First Use: 2005/05/09 First Use In Commerce: 2005/05/09 Patient support services, namely, providing educational information regarding a pharmaceutical preparation for the prevention and treatment of bone diseases; patient support services via the Internet, namely, providing educational information regarding a pharmaceutical preparation for the prevention and treatment of bone diseases		

Attachments	78764188#TMSN.jpeg ( 1 page )( bytes ) 78903989#TMSN.jpeg ( 1 page )( bytes ) 78607956#TMSN.jpeg ( 1 page )( bytes ) Notice of Opposition with Exhibit.pdf ( 20 pages )(553794 bytes )
-------------	---

### Certificate of Service

The undersigned hereby certifies that a copy of this paper has been served upon all parties, at their address record by First Class Mail on this date.

Signature	/thomas j. fitzgerald/
Name	Thomas J. FitzGerald
Date	06/28/2010

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

----- X  
ROCHE THERAPEUTICS INC., :  
 :  
 : Opposer, : NOTICE OF OPPOSITION  
 :  
 : v. :  
 : OPPOSITION NO.  
DAIICHI SANKYO COMPANY, LIMITED, :  
 : Applicant. :  
 :  
----- X

Commissioner for Trademarks  
P.O. Box 1451  
Alexandria, VA 22313-1451

In the matter of the application Serial No. 77/744,250 for application of the claimed trademark BENIVAS covering “*Pharmaceutical preparations for the treatment and prevention of cardiovascular disease, atherosclerosis, diabetic nephropathy, stroke, heart attack, hypercholesterolemia, dyslipidemia, anemia, blood disorders, diabetes, thyroid function disease, metabolic disorders, cancer, oncological disease, metastasis, autoimmune disease, allergy, bacterial infection, viral infection, fungal infection, inflammation and inflammatory disease, musculoskeletal disorders, pain, osteoporosis, Alzheimer's disease, obesity, anorexia, urinary and kidney disease, respiratory disease; Diagnostic reagents and contrast media for medical use*” in International Class 5 filed by Daiichi Sankyo Company, Limited ("Applicant"), a Joint Stock Company organized and existing under the laws of Japan having an address of Chuo-ku 3-5-1, Nihonbashi Honcho, Tokyo 103-8426, Japan, which was published in the Official Gazette of

March 2, 2010, Roche Therapeutics Inc., a corporation duly organized and existing under the laws of Delaware and having a place of business at 340 Kingsland Street, Nutley, New Jersey 07110 ("Opposer") believes that it would be damaged by registration of said application and hereby opposes same.

The grounds for opposition are as follows:

1. Opposer is the owner of Registration No. 2,931,724 filed on January 31, 2003 and registered on March 8, 2005 for the mark BONIVA for *pharmaceutical preparation for the prevention and treatment of bone diseases*. Since at least April 2005, long prior to the acts of Applicant alleged herein. Opposer has been engaged and now is engaged in the business of distributing and selling a *pharmaceutical preparation for the prevention and treatment of bone diseases* under the trademark BONIVA, with sales of such goods amounting to nearly *two billion dollars* throughout the United States, with advertising in the approximate amount of \$450 million dollars.

2. Opposer also owns additional marks constituting a family of BONIVA marks, namely, the mark BONIVA IBANDRONATE SODIUM TABLETS ONCE-MONTHLY and Design, filed December 1, 2005 and registered on October 31, 2006 under Reg. No. 3,165,165 for *providing health information via an internet web site, namely providing educational information directed to patients and physicians regarding osteoporosis and treatment options* in Class 44, which has been in use in commerce since July of 2005; MYBONIVA, registered on April 24, 2007 under Reg. No. 3,234,766 for *patient support services, namely, providing educational information regarding a pharmaceutical preparation for the prevention and treatment of bone diseases; patient support services via the Internet, namely, providing*

*educational information regarding a pharmaceutical preparation for the prevention and treatment of bone diseases* in Class 44, which has been in use since May of 2005 and BONIVA ONCE-MONTHLY IBANDRONATE SODIUM TABLETS and Design, first used in commerce in October of 2005, filed on June 8, 2006 and registered on February 27, 2007 under Reg. No. 3,213,515 for *printed brochures in the field of prevention and treatment of bone diseases* in Class 16, all on the Principal Register of the United States Patent and Trademark Office (hereinafter “BONIVA family of marks” or “BONIVA marks”). Each of Opposer's registrations are valid and in full force and effect. Copies of the referenced BONIVA, BONIVA IBANDRONATE SODIUM TABLETS ONCE-MONTHLY and Design (in two different Classes – separate registrations) and MYBONIVA certificates of registration are attached hereto as Exhibit A.

3. Since long prior to the acts of Applicant alleged herein and the filing date of Applicant's intent-to-use application, Opposer has extensively advertised and promoted the aforesaid BONIVA product making clear and prominent use of the trademark BONIVA to identify and distinguish Opposer's product and related services provided under the BONIVA family of marks from those sold and provided by others. As a result of such advertising and promotion in the approximate amount of \$450 million dollars, Opposer has enjoyed tremendous sales of the aforesaid product for *pharmaceutical preparation for the prevention and treatment of bone diseases* offered and sold under Opposer's trademark BONIVA of nearly *two billion dollars* since its launch in April 2005, with the result that Opposer's mark BONIVA has become famous among the general public and the medical profession.

4. Since long prior to the acts of the Applicant alleged herein, the famous trademark BONIVA has been used by Opposer for the purposes of identifying and distinguishing its goods

from the goods of others, and the public and medical profession have come to know and recognize said trademark as identifying the goods of Opposer as the source thereof exclusively.

5. Since long prior to the acts of Applicant alleged herein, as a result of the care and skill exercised by Opposer in the conduct of its business, the uniform standards of high quality of the pharmaceutical preparation sold under Opposer's aforesaid famous trademark BONIVA, and the extensive advertising, promotion, sale and public acceptance thereof, such goods sold and services provided under Opposer's mark BONIVA and its BONIVA family of marks described above have acquired an outstanding reputation and said marks symbolize and embody good will of tremendous value which Opposer has created throughout the United States and elsewhere by the marketing of products and provision of related services of dependable quality and by fair and honorable dealing with the medical profession and public in the sale of such pharmaceutical preparation and provision of such related services under the BONIVA marks.

6. Applicant's application to register the claimed trademark BENIVAS was filed on May 26, 2009, under Section 1(b) and alleging a bona fide intention to use the mark in commerce in connection with "*Pharmaceutical preparations for the treatment and prevention of cardiovascular disease, atherosclerosis, diabetic nephropathy, stroke, heart attack, hypercholesterolemia, dyslipidemia, anemia, blood disorders, diabetes, thyroid function disease, metabolic disorders, cancer, oncological disease, metastasis, autoimmune disease, allergy, bacterial infection, viral infection, fungal infection, inflammation and inflammatory disease, musculoskeletal disorders, pain, osteoporosis, Alzheimer's disease, obesity, anorexia, urinary and kidney disease, respiratory disease; Diagnostic reagents and contrast media for medical use.*"

7. Upon information and belief, Applicant's use of the claimed mark BENIVAS in connection with the goods described in application Serial No. 77/744,250 will be confusingly similar to Opposer's aforesaid BONIVA marks, which cover pharmaceutical preparation for the prevention and treatment of *bone diseases* and appended service marks as used and registered by Opposer.

8. Upon information and belief, the goods for which Applicant alleges that it intends to use the name BENIVAS are identical or closely related to the product and services on and in connection with which Opposer uses its BONIVA marks, and such goods of Applicant are or will be advertised, promoted and are available or offered for sale through similar or identical channels of trade to the same or similar customer groups in the medical profession and the public, such that Applicant's claimed mark BENIVAS applied to its goods is likely to cause confusion, deception, or mistake, all to the damage of Opposer and the public.

9. Applicant's claimed mark BENIVAS so resembles Opposer's registered trademark BONIVA and its BONIVA family of marks, as to be likely, when applied to Applicant's goods, to cause confusion, deception, or mistake, all to the damage of Opposer.

10. Applicant's claimed mark BENIVAS so resembles Opposer's famous registered trademark BONIVA and Opposer's BONIVA family of marks that the medical profession and public will be likely to believe that Opposer is the source of Applicant's goods or that Opposer has authorized, sponsored, approved of, or in some other manner associated itself with the goods of Applicant, thereby causing a likelihood of confusion, all to the damage of Opposer.



11. Based upon the extensive advertising and sales of Opposer's products under the BONIVA mark, Opposer's mark has gained recognition throughout the United States, and constitutes a "famous" mark under Section 43(c) of the Federal Trademark Act.


12. Applicant's application to register BENIVAS was filed on May 26, 2009, and, therefore, is subject to the provisions of Sections 13 and 43(c) of the Lanham Act, as amended. Applicant's use and registration of the BENIVAS mark as shown in Application Serial No. 77/744,250 will dilute and lessen the capacity of Opposer's famous and distinctive BONIVA marks to identify and distinguish Opposer's goods and services from those of others, all to the damage of Opposer in violation of Sections 13 and 43(c) of the Federal Trademark Act, 15 U.S.C. §§ 1063 and 1125(c).

WHEREFORE, Opposer believes it will be damaged by the registration of BENIVAS assigned Application Serial No. 77/744,250 and respectfully requests that the registration sought by Applicant be denied, and this opposition sustained.

Respectfully submitted,

LATHROP & GAGE LLP

Dated: June 28, 2010  
New York, New York

By:   
Elizabeth Atkins  
Thomas H. Curtin  
Thomas J. FitzGerald

230 Park Avenue, Suite 1847  
New York, New York 10169  
(212) 850-6220 (tel)  
(212) 850-6221 (fax)

Attorneys for Opposer

**CERTIFICATE OF ELECTRONIC FILING**

I hereby certify that the present NOTICE OF OPPOSITION was filed electronically with the Trademark Trial and Appeal Board on June 28, 2010.

  
Thomas J. FitzGerald

**CERTIFICATE OF SERVICE**

I hereby certify that a copy of the present NOTICE OF OPPOSITION was sent via Certified mail, return receipt requested, postage prepaid, to the following address on June 28, 2010, such being the address of the Applicant's named Correspondent of record listed in the Trademark Applications and Registrations Retrieval (TARR) system as of this date for the subject Application:

KAUSHAL R. ODEDRA  
ODEDRA LAW OFFICE, PLLC  
2020 PENNSYLVANIA AVE NW # 152  
WASHINGTON, DC 20006-1811

  
Thomas J. FitzGerald

# **EXHIBIT A**

Thank you for your request. Here are the latest results from the [TARR web server](#).

This page was generated by the TARR system on 2010-06-28 12:15:15 ET

Serial Number: 78209524 [Assignment Information](#) [Trademark Document Retrieval](#)

Registration Number: 2931724

Mark (words only): BONIVA

Standard Character claim: No

Current Status: [Registered](#).

Date of Status: 2005-03-08

Filing Date: 2003-01-31

Transformed into a National Application: No

Registration Date: 2005-03-08

Register: [Principal](#)

Law Office Assigned: [LAW OFFICE 102](#)

If you are the applicant or applicant's attorney and have questions about this file, please contact the Trademark Assistance Center at [TrademarkAssistanceCenter@uspto.gov](mailto:TrademarkAssistanceCenter@uspto.gov)

Current Location: 650 -Publication And Issue Section

Date In Location: 2005-01-27

---

#### LAST APPLICANT(S)/OWNER(S) OF RECORD

---

1. [Roche Therapeutics Inc.](#)

**Address:**

[Roche Therapeutics Inc.](#)  
[340 Kingsland Street](#)  
[Nutley, NJ 07110](#)  
[United States](#)

**Legal Entity Type:** [Corporation](#)

**State or Country of Incorporation:** [Delaware](#)

**Phone Number:** [973-235-2122](#)

**Fax Number:** [973-235-5450](#)

---

#### GOODS AND/OR SERVICES

---

**International Class:** [005](#)

**Class Status:** [Active](#)

[pharmaceutical preparation for the prevention and treatment of bone diseases](#)

**Basis:** [1\(a\)](#)

**First Use Date:** [2004-08-24](#)

**First Use in Commerce Date:** [2004-08-24](#)

---

### ADDITIONAL INFORMATION

---

**Prior Registration Number(s):**  
[2106772](#)

---

### MADRID PROTOCOL INFORMATION

---

(NOT AVAILABLE)

---

### PROSECUTION HISTORY

---

**NOTE: To view any document referenced below, click on the link to "Trademark Document Retrieval" shown near the top of this page.**

[2009-11-23 - Attorney Revoked And/Or Appointed](#)

[2009-11-23 - TEAS Revoke/Appoint Attorney Received](#)

[2005-03-08 - Registered - Principal Register](#)

[2004-11-13 - Law Office Registration Review Completed](#)

[2004-11-10 - Assigned To LIE](#)

[2004-11-08 - Assigned To LIE](#)

[2004-10-04 - Assigned To LIE](#)

[2004-09-27 - Allowed for Registration - Principal Register \(SOU accepted\)](#)

[2004-09-27 - Assigned To Examiner](#)

[2004-09-23 - Statement Of Use Processing Complete](#)

[2004-09-23 - Extension 2 granted](#)

[2004-09-09 - Use Amendment Filed](#)

[2004-09-09 - Extension 2 filed](#)

[2004-09-09 - TEAS Statement of Use Received](#)

[2004-09-09 - TEAS Extension Received](#)

[2004-04-29 - Extension 1 granted](#)

[2004-04-22 - Extension 1 filed](#)

[2004-04-22 - TEAS Extension Received](#)

[2003-12-16 - Noa Mailed - SOU Required From Applicant](#)

## Latest Status Info

2003-09-23 - Published for opposition

2003-09-03 - Notice of publication

2003-07-21 - Approved For Pub - Principal Register

2003-07-21 - Assigned To Examiner

---

**ATTORNEY/CORRESPONDENT INFORMATION**

---

**Attorney of Record**

Timothy R. Schwartz

**Correspondent**

Timothy R. Schwartz

Genentech, Inc.

1 DNA Way

South San Francisco CA 94080-4990

Phone Number: 650-225-7467

Fax Number: 650-952-9881

---

Thank you for your request. Here are the latest results from the [TARR web server](#).

This page was generated by the TARR system on 2010-06-28 12:16:50 ET

Serial Number: 78764188 [Assignment Information](#) [Trademark Document Retrieval](#)

Registration Number: 3165165

Mark



(words only): [BONIVA IBANDRONATE SODIUM TABLETS ONCE-MONTHLY](#)

Standard Character claim: No

Current Status: [Registered](#).

Date of Status: [2006-10-31](#)

Filing Date: [2005-12-01](#)

Transformed into a National Application: No

Registration Date: [2006-10-31](#)

Register: [Principal](#)

Law Office Assigned: [LAW OFFICE 101](#)

If you are the applicant or applicant's attorney and have questions about this file, please contact the Trademark Assistance Center at [TrademarkAssistanceCenter@uspto.gov](mailto:TrademarkAssistanceCenter@uspto.gov)

Current Location: [650 -Publication And Issue Section](#)

Date In Location: [2006-10-31](#)

---

#### LAST APPLICANT(S)/OWNER(S) OF RECORD

---

1. [Roche Therapeutics Inc.](#)

Address:

[Roche Therapeutics Inc.](#)

[340 Kingsland Street](#)

[Nutley, NJ 07110](#)

[United States](#)

Legal Entity Type: [Corporation](#)

State or Country of Incorporation: [Delaware](#)

Phone Number: [973-235-2122](#)

**Fax Number:** [973-235-5450](tel:973-235-5450)

---

### GOODS AND/OR SERVICES

---

**International Class:** [044](#)

**Class Status:** [Active](#)

[providing health information via an internet web site, namely providing educational information directed to patients and physicians regarding osteoporosis and treatment options](#)

**Basis:** [1\(a\)](#)

**First Use Date:** [2005-07-26](#)

**First Use in Commerce Date:** [2005-07-26](#)

---

### ADDITIONAL INFORMATION

---

**Disclaimer:** ["ONCE-MONTHLY", "IBANDRONATE SODIUM TABLETS"](#)

**Design Search Code(s):**

[02.03.02](#) - Silhouettes of women; Women depicted as shadows or silhouettes of women

[02.09.12](#) - Flying, humans (self-propelled); Humans, including men, women and children, depicted flying (self-propelled)

**Prior Registration Number(s):**

[2931724](#)

---

### MADRID PROTOCOL INFORMATION

---

(NOT AVAILABLE)

---

### PROSECUTION HISTORY

---

**NOTE:** To view any document referenced below, click on the link to "Trademark Document Retrieval" shown near the top of this page.

[2009-11-23 - Attorney Revoked And/Or Appointed](#)

[2009-11-23 - TEAS Revoke/Appoint Attorney Received](#)

[2006-10-31 - Registered - Principal Register](#)

[2006-08-15 - Published for opposition](#)

[2006-07-26 - Notice of publication](#)

[2006-06-26 - Law Office Publication Review Completed](#)

[2006-06-23 - Assigned To LIE](#)

[2006-06-12 - Approved for Pub - Principal Register \(Initial exam\)](#)

[2006-06-07 - Examiner's Amendment Entered](#)

[2006-06-07 - Examiners amendment e-mailed](#)



[2006-06-07 - Examiners Amendment -Written](#)

[2006-06-03 - Assigned To Examiner](#)

[2005-12-08 - Notice Of Design Search Code Mailed](#)

[2005-12-07 - New Application Entered In Tram](#)

---

**ATTORNEY/CORRESPONDENT INFORMATION**

---

**Attorney of Record**

[Timothy R. Schwartz](#)

**Correspondent**

[Timothy R. Schwartz](#)

[Genentech, Inc.](#)

[1 DNA Way](#)

[South San Francisco CA 94080-4990](#)

[Phone Number: 650-225-7467](#)

[Fax Number: 650-952-9881](#)

---

Thank you for your request. Here are the latest results from the [TARR web server](#).

This page was generated by the TARR system on 2010-06-28 12:17:39 ET

Serial Number: 78903989 [Assignment Information](#) [Trademark Document Retrieval](#)

Registration Number: 3213515

Mark



(words only): [ONCE-MONTHLY BONIVA IBANDRONATE SODIUM TABLETS](#)

Standard Character claim: No

Current Status: [Registered](#).

Date of Status: [2007-02-27](#)

Filing Date: [2006-06-08](#)

Transformed into a National Application: No

Registration Date: [2007-02-27](#)

Register: [Principal](#)

Law Office Assigned: [LAW OFFICE 117](#)

If you are the applicant or applicant's attorney and have questions about this file, please contact the Trademark Assistance Center at [TrademarkAssistanceCenter@uspto.gov](mailto:TrademarkAssistanceCenter@uspto.gov)

Current Location: [650 -Publication And Issue Section](#)

Date In Location: [2007-02-27](#)

---

#### LAST APPLICANT(S)/OWNER(S) OF RECORD

---

1. [Roche Therapeutics Inc.](#)

Address:

[Roche Therapeutics Inc.](#)

[340 Kingsland Street](#)

[Nutley, NJ 07110](#)

[United States](#)

Legal Entity Type: [Corporation](#)

State or Country of Incorporation: [Delaware](#)

Phone Number: [973-235-2122](#)

**Fax Number:** 973-235-5450

---

### GOODS AND/OR SERVICES

---

**International Class:** 016

**Class Status:** Active

printed brochures in the field of the prevention and treatment of bone diseases

**Basis:** 1(a)

**First Use Date:** 2005-10-12

**First Use in Commerce Date:** 2005-10-12

---

### ADDITIONAL INFORMATION

---

**Disclaimer:** "ONCE-MONTHLY" and "IBANDRONATE SODIUM TABLETS"

**Description of Mark:** The mark consists of stylized figure of a woman.

**Design Search Code(s):**

**02.01.33** - Grotesque men formed by letters, numbers, punctuation or geometric shapes; Stick figures

**Prior Registration Number(s):**

2931724

---

### MADRID PROTOCOL INFORMATION

---

(NOT AVAILABLE)

---

### PROSECUTION HISTORY

---

**NOTE: To view any document referenced below, click on the link to "Trademark Document Retrieval" shown near the top of this page.**

2009-11-23 - Attorney Revoked And/Or Appointed

2009-11-23 - TEAS Revoke/Appoint Attorney Received

2007-02-27 - Registered - Principal Register

2006-12-12 - Published for opposition

2006-11-22 - Notice of publication

2006-10-19 - Law Office Publication Review Completed

2006-10-19 - Assigned To LIE

2006-10-03 - Approved for Pub - Principal Register (Initial exam)

2006-09-28 - Examiner's Amendment Entered

2006-09-28 - Examiners amendment e-mailed

2006-09-28 - Examiners Amendment -Written

2006-09-28 - Assigned To Examiner

2006-06-15 - Notice Of Design Search Code Mailed

2006-06-14 - New Application Entered In Tram

---

**ATTORNEY/CORRESPONDENT INFORMATION**

---

**Attorney of Record**

Timothy R. Schwartz

**Correspondent**

Timothy R. Schwartz

Genentech, Inc.

1 DNA Way

South San Francisco CA 94080-4990

Phone Number: 650-225-7467

Fax Number: 650-952-9881

---

Thank you for your request. Here are the latest results from the [TARR web server](#).

This page was generated by the TARR system on 2010-06-28 12:18:09 ET

Serial Number: 78607956 [Assignment Information](#) [Trademark Document Retrieval](#)

Registration Number: 3234766

Mark

MYBONIVA

(words only): MYBONIVA

Standard Character claim: Yes

Current Status: Registered.

Date of Status: 2007-04-24

Filing Date: 2005-04-13

Transformed into a National Application: No

Registration Date: 2007-04-24

Register: Principal

Law Office Assigned: LAW OFFICE 113

If you are the applicant or applicant's attorney and have questions about this file, please contact the Trademark Assistance Center at [TrademarkAssistanceCenter@uspto.gov](mailto:TrademarkAssistanceCenter@uspto.gov)

Current Location: 650 -Publication And Issue Section

Date In Location: 2007-03-19

---

#### LAST APPLICANT(S)/OWNER(S) OF RECORD

---

1. [Roche Therapeutics Inc.](#)

**Address:**

[Roche Therapeutics Inc.](#)

340 Kingsland Street

Nutley, NJ 07110

United States

**Legal Entity Type:** Corporation

**State or Country of Incorporation:** Delaware

**Phone Number:** 973-235-2122

**Fax Number:** [973-235-5450](tel:973-235-5450)

---

### GOODS AND/OR SERVICES

---

**International Class:** [044](#)

**Class Status:** [Active](#)

[Patient support services, namely, providing educational information regarding a pharmaceutical preparation for the prevention and treatment of bone diseases; patient support services via the Internet, namely, providing educational information regarding a pharmaceutical preparation for the prevention and treatment of bone diseases](#)

**Basis:** [1\(a\)](#)

**First Use Date:** [2005-05-09](#)

**First Use in Commerce Date:** [2005-05-09](#)

---

### ADDITIONAL INFORMATION

---

**Prior Registration Number(s):**

[2931724](#)

---

### MADRID PROTOCOL INFORMATION

---

(NOT AVAILABLE)

---

### PROSECUTION HISTORY

---

**NOTE: To view any document referenced below, click on the link to "Trademark Document Retrieval" shown near the top of this page.**

[2009-11-23 - Attorney Revoked And/Or Appointed](#)

[2009-11-23 - TEAS Revoke/Appoint Attorney Received](#)

[2007-04-24 - Registered - Principal Register](#)

[2007-03-08 - Law Office Registration Review Completed](#)

[2007-03-07 - Assigned To LIE](#)

[2007-02-06 - Allowed for Registration - Principal Register \(SOU accepted\)](#)

[2007-01-25 - Statement Of Use Processing Complete](#)

[2007-01-25 - Extension 2 granted](#)

[2006-11-16 - Use Amendment Filed](#)

[2006-11-16 - Extension 2 filed](#)

[2006-11-16 - TEAS Extension Received](#)

[2006-11-16 - TEAS Statement of Use Received](#)

[2006-10-31 - Extension 1 granted](#)

2006-09-27 - Extension 1 filed

2006-09-27 - TEAS Extension Received

2006-04-04 - Noa Mailed - SOU Required From Applicant

2006-01-10 - Published for opposition

2005-12-21 - Notice of publication

2005-11-21 - Law Office Publication Review Completed

2005-11-18 - Assigned To LIE

2005-11-14 - Approved For Pub - Principal Register

2005-11-10 - Examiners amendment e-mailed

2005-11-10 - Examiners Amendment -Written

2005-11-10 - Assigned To Examiner

2005-04-20 - New Application Entered In Tram

---

**ATTORNEY/CORRESPONDENT INFORMATION**

---

**Attorney of Record**

Timothy R. Schwartz

**Correspondent**

Timothy R. Schwartz

Genentech, Inc.

1 DNA Way

South San Francisco CA 94080-4990

Phone Number: 650-225-7467

Fax Number: 650-952-9881

---